Urothelial Ca immunotherapy approved for first-line use – ModernMedicine
|
Urothelial Ca immunotherapy approved for first-line use
ModernMedicine The regulatory agency’s decision makes atezolizumab the only cancer immunotherapy agent approved for initial treatment of urothelial carcinoma in patients who are ineligible for cisplatin. In May 2016, atezolizumab became the first immunotherapy agent … |
Bloomberg |
Companies Racing to Use Crispr to Fight Disease
Bloomberg Crispr is a new gene-editing tool that could transform biotechnology. Bloomberg’s Doni Bloomfield spoke with the three public companies located in Cambridge, Massachusetts that are racing to use Crispr in people. (Source: Bloomberg) … |
Technology Networks |
Oxford Genetics Licenses CRISPR IP From ERS Genomics
GenomeWeb “Licensing the CRISPR gene-editing technology from ERS Genomics is another step on our journey to establishing the most efficient and integrated service portfolio in this sector,” Oxford Genetics CCO Paul Brooks said in a statement. “We are excited to … Oxford Genetics Licenses CRISPR Gene Editing Technology from ERS GenomicsPharmaceutical Technology Magazine (press release) (blog) |
|
First-In-Human Clinical Trial Aims to Extend Remission for Children and Young Adults With Leukemia Treated With T …
Newswise (press release) The new phase 1 pilot study, PLAT-03, will examine the feasibility and safety of administering a second T-cell product intended to increase the long-term persistence of the patient’s chimeric antigen receptor (CAR) T cells that were reprogrammed to … |